Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.
作者信息
Miners John O, Polasek Thomas M
机构信息
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.
出版信息
Clin Pharmacol Ther. 2025 Aug;118(2):301-303. doi: 10.1002/cpt.3734. Epub 2025 May 26.
Abstract
摘要
相似文献
1
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.
Clin Pharmacol Ther. 2025 Aug;118(2):301-303. doi: 10.1002/cpt.3734. Epub 2025 May 26.
2
First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics.
J Pharm Sci. 2024 Aug;113(8):2641-2650. doi: 10.1016/j.xphs.2024.05.021. Epub 2024 May 24.
3
species on palms - integrative taxonomic approach for species boundaries delimitation in the genus , with the description of .
Stud Mycol. 2024 Dec;109:487-594. doi: 10.3114/sim.2024.109.08. Epub 2024 Oct 23.
4
Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.
Clin Pharmacol Ther. 2025 Aug;118(2):428-437. doi: 10.1002/cpt.3686. Epub 2025 Apr 28.
5
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization.
Pharm Res. 2025 Mar 28. doi: 10.1007/s11095-025-03849-9.
6
Physiologically-based pharmacokinetic modeling of rosuvastatin in Chinese: Predicting the impact of SLCO1B1 and ABCG2 genetic variants and hepatic impairment on drug exposure.
J Pharm Sci. 2025 Aug;114(8):103866. doi: 10.1016/j.xphs.2025.103866. Epub 2025 Jun 7.
7
First Report of causing leaf spot on in China.
Plant Dis. 2025 Jun 27. doi: 10.1094/PDIS-05-25-0972-PDN.
8
Optimizing Extended-release Formulation of l-tetrahydropalmatine Based on In Vivo Outcomes Using Integrated Modeling Approaches.
AAPS PharmSciTech. 2025 Jun 26;26(6):170. doi: 10.1208/s12249-025-03165-w.
9
Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment.
Clin Transl Sci. 2025 Jul;18(7):e70299. doi: 10.1111/cts.70299.
10
Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.
PLoS Comput Biol. 2025 Jul 16;21(7):e1013247. doi: 10.1371/journal.pcbi.1013247.
本文引用的文献
1
Physiologically based pharmacokinetic modeling of small molecules: How much progress have we made?
Drug Metab Dispos. 2025 Jan;53(1):100013. doi: 10.1124/dmd.123.000960. Epub 2024 Nov 22.
2
Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration.
Clin Pharmacol Ther. 2025 Aug;118(2):497-509. doi: 10.1002/cpt.3529. Epub 2024 Dec 14.
3
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards.
Clin Pharmacokinet. 2025 Jan;64(1):155-170. doi: 10.1007/s40262-024-01457-1. Epub 2024 Dec 10.
4
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.
Pharmacol Ther. 2023 Aug;248:108459. doi: 10.1016/j.pharmthera.2023.108459. Epub 2023 May 30.
5
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.
Pharmacol Ther. 2021 Feb;218:107689. doi: 10.1016/j.pharmthera.2020.107689. Epub 2020 Sep 25.
6
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Biochem Pharmacol. 2017 Apr 1;129:85-95. doi: 10.1016/j.bcp.2017.01.002. Epub 2017 Jan 6.
7
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.
Drug Metab Dispos. 2010 Nov;38(11):1907-11. doi: 10.1124/dmd.110.033829. Epub 2010 Jul 28.
8
Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism.
Drug Metab Dispos. 2007 Dec;35(12):2270-80. doi: 10.1124/dmd.107.017806. Epub 2007 Sep 26.
9
Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin.
Biochem J. 2003 May 1;371(Pt 3):897-905. doi: 10.1042/BJ20030034.
10
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.
J Biol Chem. 2001 Mar 30;276(13):9626-30. doi: 10.1074/jbc.M004968200. Epub 2000 Dec 27.
Zotero 插件